Latest Non Dilutive Funding News

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.

Litchfield Minerals secured US$500,000 from BHP's Xplor program and delivered thick copper-zinc intercepts at Oonagalabi, expanding its mineral system model despite operational challenges.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Bayan Mining and Minerals delivers strong rare earth assay results from its Desert Star project, advances permitting and drill planning at Bayan Springs South, and strengthens its leadership and strategic positioning.

Battery Age Minerals has joined the U.S. Defense Industrial Base Consortium, positioning itself at the forefront of securing critical germanium supply amid escalating export restrictions from China. The company’s dual-continental assets in Austria and Utah and its technology initiatives aim to address strategic vulnerabilities in defence and semiconductor supply chains.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Newcam Minerals has exercised its option to acquire a 60% interest in Alchemy Resources' Bryah Basin Iron Ore Project, paying $500,000 and taking operational control. Alchemy retains a 40% free-carried stake to a Decision to Mine, reducing its development risk while preserving upside exposure.

West Cobar Metals (ASX: WC1) is progressing its U.S.-focused critical minerals strategy by formally engaging with U.S. government funding programs and partnering with Washington D.C.-based advisor GreenMet. The company’s Australian projects contain key minerals aligned with U.S. supply chain priorities, while it evaluates potential U.S. acquisitions to expand its footprint.

Red Mountain Mining Ltd is set to recommence exploration at its US antimony projects following winter, supported by US government initiatives and strengthened by a new advisory appointment. The company plans systematic geological mapping and sampling across multiple projects, aiming to advance towards drill testing and resource definition.